Acinetobacter baumannii has emerged as a worldwide problem as a nosocomial pathogen in hospitalized patients. Acinetobacter spp. can cause a multitude of infections including pneumonia, bacteremia, meningitis, urinary tract infections, and skin and soft tissue infections, and the mortality associated with these infections is high. Isolates resistant to almost all commercially available antimicrobials have been identified, thus limiting treatment options. Isolates of Acinetobacter received in the microbiology laboratory over a period of one year were processed, identified by conventional standard methods and antimicrobial susceptibility was performed according to CLSI guidelines. A total of 62 isolates were identified. Maximum () were from respiratory specimens and indoor patients. Multi drug resistance was observed in isolates. Drug resistance is a major therapeutic concern in Acinetobacter isolates. Even though no pan drug resistant organism was encountered in our study, still judicious antimicrobial use and antimicrobial stewardship program is strongly advocated to curb the growing threat of resistance. | Prevalence and antibiogram of acinetobacter infections: An experience from a teaching institute of rural setting, in central India
